Mineralys Therapeutics, Inc. balance sheet MLYS

Annual Quarterly

As of Sep 30, 2026, Mineralys Therapeutics, Inc. had total assets of $630.1 million and total liabilities of $126.3 million. Total assets were up 5.0% from a year earlier. Stockholders' equity was $503.8 million. It held $101.3 million in cash and investments against $100,000 of total debt, net cash of $101.2 million. The current ratio, current assets divided by current liabilities, was 11.83.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Assets
Cash	101 -53.5%	138 +35.8%	113 -31.7%	173 +51.6%	218 +123.7%	102 +50.0%	165 +82.5%	114 +131.4%
Long-term investments	—	—	—	—	—	—	—	0
Cash and investments	101 -53.5%	138 +35.8%	113 -31.7%	173 +51.6%	218 +123.7%	102 +50.0%	165 +82.5%	114 +131.4%
Total current assets	628 +4.7%	666 +98.6%	652 +84.1%	661 +222.1%	600 +124.0%	335 +5.4%	355 +2.2%	205 -17.6%
Property and equipment, net	0 +200.0%	0 +22.7%	0 -15.8%	0 -28.3%	0 -89.9%	0 -47.6%	0 -25.5%	0
Total assets	630 +5.0%	668 +98.9%	653 +83.9%	662 +221.4%	600 +123.6%	336 +5.4%	355 +2.2%	206 -18.2%
Liabilities and equity
Accounts payable	1 -34.2%	1 -66.3%	1 +199.2%	2 +321.1%	1 -63.9%	3 +85.4%	0 -91.2%	0 -20.3%
Total current liabilities	53 +125.7%	19 -12.9%	15 +10.0%	15 +3.2%	24 -24.9%	22 -21.9%	13 -30.3%	15 +39.7%
Total liabilities	126	117	—	—	—	—	—	—
Stockholders' equity	504 -12.6%	551 +75.7%	638 +86.8%	647 +238.1%	576 +143.3%	314 +8.1%	342 +4.1%	191 -20.7%
Debt
Long-term debt	0	0	—	—	—	—	—	—
Total debt	0	0	—	—	—	—	—	—
Net cash	101	138	—	—	—	—	—	—
Ratios
Current ratio	11.83x	34.46x	44.33x	43.76x	25.50x	15.12x	26.48x	14.02x
Debt to equity	0.00x	0.00x	—	—	—	—	—	—
Return on equity	-73.44%	-63.45%	-23.78%	-23.91%	-29.73%	-60.84%	-55.19%	-92.97%
Return on assets	-58.71%	-52.34%	-23.25%	-23.37%	-28.56%	-56.82%	-53.11%	-86.36%
Book value per share	5.69	6.24	7.74	7.93	7.30	4.77	5.26	3.84

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: MLYS (Nasdaq)
Fiscal year ends: December 31
Headquarters: Radnor, PA
SEC filer status: Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK: 1933414

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.